Darnitsa: Why is it important to treat hypertension?

In the world and in Ukraine, arterial hypertension ranks first among all cardiovascular diseases and is the leader among risk factors for death.¹ Given the prevalence of the problem, the pharmaceutical company "Darnitsa" expands its portfolio and brings to the market another antihypertensive drug to combat the disease.

Over the past 30 years, the number of adults in the world with hypertension has doubled: from 650 million to 1.28 billion.² Percent of the spread of the disease is about 30-45% among the adult population. The prevalence of arterial hypertension begins to increase with age and reaches 60% in patients over 60 years of age.³ High blood pressure is a leading global factor in premature death and one of the WHO's global goals for the Prevention of noncommunicable diseases.⁴

Arterial hypertension (AH) ranks first among all cardiovascular diseases in Ukraine. The prevalence of this disease among urban residents is 30%, and 36% is in rural areas. The share of persons of working age is 43.5% of the total number of registered patients.⁵

Factors affecting the development of AH are sedentary lifestyle, bad habits, poor nutrition, overweight and obesity.³

Why is it important to treat hypertension?

• According to the results of prospective studies, the presence of hypertension increases the risk of overall mortality: in men – by 4.5 times, in women – by 2.0 times.⁵
• Effective treatment of arterial hypertension reduces the risk of heart failure by 50%, stroke - by 40%, and cardiovascular death - by 20%.⁶
• Uncontrolled arterial hypertension is considered one of the most significant factors in reducing the life expectancy of the population.

The pharmaceutical company "Darnitsa" has a wide portfolio of Cardiological drugs, in particular antihypertensive agents. In October, the portfolio was expanded with a new drug "Ramiton A"⁷ for the treatment of arterial hypertension in adult patients whose blood pressure is properly controlled by ramipril and amlodipine.

"Ukraine belongs to the group of countries with a high risk of mortality due to cardiovascular diseases on the international SCORE scale. That is why we continue to expand our product portfolio of cardiac drugs with effective means. "Ramiton A" is a fixed combination of ramipril and amlodipine, which means it will improve adherence to treatment," said Igor Nykyforchyn, director of medical affairs at "Darnitsa" pharmaceutical company.

Information

Private Joint Stock Company Pharmaceutical company "Darnitsa" was founded in 1930. Since 1998, "Darnitsa" has been the leader in Ukraine in terms of drug production in physical terms. Strategic areas of portfolio development include cardiology, neurology, and pain management. During 2015-2020, "Darnitsa" launched 50 pharmaceutical brands on the market.

*The above information is intended exclusively for distribution in specialized publications intended for medical institutions and doctors, as well as at conferences and seminars on medical topics.

¹ Kearney PM, et. al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–223 // https://ourworldindata.org/burden-of-disease, 2017

² Hypertension Has Doubled Globally Over 30 Years by Megan Brooks, August 25, 2021 // https://www.medscape.com/viewarticle/957242

³ NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017

⁴ Williams B,.et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104

⁵ Unified clinical protocol of primary, emergency and secondary (specialized) medical care, arterial hypertension, 2016

⁶ Moser M., Hebert P., 1996; James P. A. et al., 2013

⁷ Instructions for medical use of the drug "Ramiton A" Р.П № UA/18731/01/03, № UA/18731/01/01, № UA/18731/01/04, № UA/18731/01/02. Available on prescription.